What is the Sophia Genetics SA stock price forecast?

Sophia Genetics SA is currently trading at $4.93. View real-time AI analysis on Alpha Lenz.

What is Sophia Genetics SA insider trading activity?

View the latest insider trading data for Sophia Genetics SA on Alpha Lenz.

What is Sophia Genetics SA's P/E ratio?

Sophia Genetics SA's P/E ratio is -4.2.

Sophia Genetics SA

NASDAQ · SOPH

$4.93-0.08(-1.60%)Pre-market

Ask about Sophia Genetics SA's future dividend policy...

Alpha Chat Insight

“Sophia Genetics SA trades at a P/E of -4.2 (undervalued) with modest ROE of -110.0%. 3Y revenue CAGR of 17.6% highlights clear growth momentum.”

Ask for details →

Company Overview

Sophia Genetics SA is a global leader in data-driven medicine focused on enabling healthcare institutions to leverage artificial intelligence and data analytics to enhance clinical diagnosis. The company's main purpose is to democratize data-driven medicine, making genomic and other types of patient data insights accessible and actionable for healthcare providers worldwide. Sophia Genetics serves various sectors within the medical field, including oncology, cardiology, and rare genetic disorders, by providing powerful data interpretation solutions that empower personalized treatment plans. Founded in 2011, the company aims to improve patient outcomes by ensuring data standardization and accessibility across global healthcare networks. Its platform integrates a wide array of medical data from genomic sequences to imaging data, allowing for a comprehensive approach to medical data analysis and enhanced collaboration among medical professionals. By making complex medical data easily interpretable, Sophia Genetics plays a significant role in the growing field of precision medicine, driving innovation in healthcare diagnostics and treatment methodologies.

CEODr. Jurgi Camblong M.B.A., Ph.D.

Websitehttps://www.sophiagenetics.com

SectorHealthcare

IndustryHealth Information Services

Employees423

Company Statistics

FY 2025

Profile

$332.97MMarket Cap

$77.27MRevenue

0.00Shares Out

423Employees

Margins

67.40%Gross

-77.01%EBITDA

-91.76%Operating

-100.28%Pre-Tax

-102.24%Net

Valuation

-4.21P/E

7.06P/B

4.31EV/Sales

-5.47EV/EBITDA

-7.48P/FCF

Growth (CAGR)

17.56%Rev 3Yr

22.16%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-49.63%ROA

-110.00%ROE

-45.82%ROIC

Financial Health

$70.29MCash & Cash Equivalents

$45.60MNet Debt

245.81%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Sophia Genetics SA trades at a P/E of -4.2 (undervalued) with modest ROE of -110.0%. 3Y revenue CAGR of 17.6% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Sophia Genetics SA (ticker: SOPH) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 423 employees. Market cap is $333M.

The current price is $4.93 with a P/E ratio of -4.21x and P/B of 7.06x.

ROE is -110.00% and operating margin is -91.76%. Annual revenue is $77M.